VEGFA and lung cancer: In the treatment of lung cancer, recent years have seen a remarkable boom of targeted therapy, focused mainly on the EGFR inhibition with erlotinib and gefitinib, and neoangiogenesis inhibition with VEGF inhibitor bevacizumab.